Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis

@article{Fruyt2012SecondGA,
  title={Second generation antipsychotics in the treatment of bipolar depression: a systematic review and meta-analysis},
  author={J. De Fruyt and E. Deschepper and K. Audenaert and E. Constant and M. Floris and W. Pitchot and P. Sienaert and D. Souery and S. Claes},
  journal={Journal of Psychopharmacology},
  year={2012},
  volume={26},
  pages={603 - 617}
}
Depressive symptoms and episodes dominate the course of bipolar disorder. However, the therapeutic armamentarium for bipolar depression is limited. Recent evidence points to the efficacy of second generation antipsychotics (SGAs) for the treatment of bipolar depression. We conducted a systematic review and meta-analysis of the efficacy and safety of SGAs (randomized, double-blind, placebo-controlled trials; used in monotherapy) in the treatment of adult patients with bipolar depression… Expand
A systematic review of the evidence for the treatment of acute depression in bipolar I disorder
TLDR
Evidence for the acute treatment of depression in bipolar I disorder is examined, focusing on double-blind, placebo-controlled studies with a definite primary outcome measure and published in peer review journals, to better understand the role of antidepressants. Expand
Acceptability of Acute and Maintenance Pharmacotherapy of Bipolar Disorder: A Systematic Review of Randomized, Double-Blind, Placebo-Controlled Clinical Trials.
TLDR
All medications studied in bipolar disorder were relatively well tolerated during different phases of treatment; however, the risk for short- and long-term WG and somnolence varied widely among included psychotropics. Expand
Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials
TLDR
There was a statistically significant higher risk of EPS-related AEs and a slight increase in mean body weight with cariprazine, and further clinical and post-marketing pharmacovigilance studies are needed to investigate the long-term safety of carIPrazine. Expand
Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis.
TLDR
Although no benefits were found in terms of symptoms improvement, response and remission rates, there were clear disadvantages in prescribing higher rather than lower doses of selected SGAs, and data need to be integrated with individual patient characteristics to optimize management of acute bipolar depression. Expand
The preclinical discovery and development of quetiapine for the treatment of mania and depression
TLDR
Pre-clinical studies on QTP’s anti-manic effects are still scarce, and the role of the QTP metabolite norquetiapine in modulating non-neurotransmitter systems also needs to be further addressed. Expand
Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
TLDR
This overview stipulates the effectiveness of lurasidone in the acute treatment of Type I bipolar depression overall, and recommendations for future research should include further controlled trials of extended duration. Expand
Overview of antidepressant treatment of bipolar depression.
TLDR
Overall efficacy was significantly greater with antidepressants than with placebo-treatment and not less than was found in trials for unipolar major depression, and risks of non-spontaneous mood-switching specifically associated with antidepressant treatment are less than appears to be widely believed. Expand
Treatment of bipolar disorder
TLDR
Current developments in the acute and long-term treatment of bipolar disorder are reviewed and promising future routes to therapeutic innovation are identified and existing psychotherapy protocols need to be made briefer and more efficient for improved scalability and sustainability in widespread implementation. Expand
Management of bipolar I depression: clinical utility of lurasidone
TLDR
Longer term safety data obtained in 6 months long, open continuation observation periods, suggest that metabolic related elevations in weight, glucose, and lipids are absent or minimal. Expand
Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial
TLDR
Factors that may have affected the outcome of the trial were identified and helped to inform the design and conduct of subsequent phase 2b/3 clinical trials of cariprazine in bipolar depression. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 61 REFERENCES
Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
TLDR
Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards and Rapid onset of action seems to be a common feature of atypical antipsychotic in bipolar depression. Expand
Clinical highlights in bipolar depression: focus on atypical antipsychotics.
TLDR
Subpopulation analyses suggest that quetiapine monotherapy and the olanzapine plus fluoxetine combination appear to be effective in treating depression in patients with a rapid-cycling course, and the magnitude of improvement in depressive symptoms in the bipolar I population appears to be larger for queto- monotherapy. Expand
Bipolar depression: a new role for atypical antipsychotics?
  • P. Keck
  • Psychology, Medicine
  • Bipolar disorders
  • 2005
TLDR
Results from an 8-week, randomized placebo-controlled trial in patients with bipolar I and II disorder who were experiencing a bipolar depressive episode showed that quetiapine had significantly greater efficacy compared with placebo in improving the core symptoms of depression, including suicidal thoughts. Expand
Atypical antipsychotics in bipolar disorder: systematic review of randomised trials
TLDR
Atypical antipsychotics are effective in treating both phases of bipolar disorder compared with placebo, and as effective as established drug therapies. Expand
The armamentarium of treatments for bipolar disorder: a review of the literature.
  • D. Cousins, A. Young
  • Psychology, Medicine
  • The international journal of neuropsychopharmacology
  • 2007
TLDR
A growing role for atypical antipsychotics in the treatment of bipolar disorder is suggested and further data are anticipated. Expand
Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials.
TLDR
Combining SGAs and MSs is the most efficacious treatment of acute mania, and adding antipsychotic agents to MS treatment was significantly more effective than treatment with MSs alone. Expand
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
TLDR
The use of adjunctive, standard antidepressant medication, as compared with the use of mood stabilizers, was not associated with increased efficacy or with increased risk of treatment-emergent affective switch. Expand
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
TLDR
Olanzapine is more effective than placebo, and combined olanzapine-fluoxetine isMore effective than olanZapine and placebo in the treatment of bipolar I depression without increased risk of developing manic symptoms. Expand
Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study.
TLDR
Quetiapine monotherapy shows efficacy in treating anxiety symptoms in bipolar I depression; however, the anxiolytic effects in bipolar II disorder require further investigation. Expand
Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone.
TLDR
Post hoc secondary analyses suggest that lamotrigine may be superior to inositol and risperidone in improving treatment-resistant bipolar depression. Expand
...
1
2
3
4
5
...